GlassScriptPhysician profile
Susan Schreiber
NPI 1013662725
$4,252.66
in general payments reported to CMS, 2019-2025
26 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 97% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $336 · 2023: $1,097 · 2024: $1,524 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,904 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,903.61 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,614.59 | 2022-2025 | Briviact, Nayzilam, Fintepla |
| Jazz Pharmaceuticals INC. | $591.21 | 2023-2025 | |
| Neurelis, INC. | $447.28 | 2024-2025 | Valtoco |
| Regeneron Healthcare Solutions, INC. | $246.77 | 2022-2025 | Dupixent |
| Genzyme Corporation | $185.43 | 2022-2024 | |
| Azurity Pharmaceuticals, INC. | $142.38 | 2022-2025 | Triptodur, Zonisade |
| Eisai INC. | $116.84 | 2022-2023 | |
| Immedica Pharma US, INC. | $112.35 | 2022-2025 | Ztalmy |
| Xeris Pharmaceuticals, INC. | $102.16 | 2022-2024 | Gvoke Hypopen |
| Abbvie INC. | $96.68 | 2022-2024 | |
| Livanova USA, INC. | $82.27 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Aucta Pharmaceuticals, INC. | $74.89 | 2025 | Motpoly Xr |
| Acadia Pharmaceuticals INC | $74.65 | 2024-2025 | Daybue |
| Upsher-Smith Laboratories LLC | $50.38 | 2025 | |
| Tolmar, INC. | $47.63 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $42.31 | 2023 | Dexcom G6 Transmitter |
| Albireo Pharma, INC. | $34.98 | 2023 | Bylvay |
| Takeda Pharmaceuticals U.S.A., INC. | $31.82 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $26.31 | 2022 | |
| Qol Medical, LLC | $23.50 | 2023 | Sucraid |
| Biocodex, INC. | $22.87 | 2024 | |
| Kyowa Kirin, INC. | $20.91 | 2023 | Crysvita |
| Mirum Pharmaceuticals, INC. | $19.66 | 2024 | Livmarli |
| Alexion Pharmaceuticals, INC. | $17.84 | 2024 | Strensiq |
| Ascendis Pharma Endocrinology INC | $13.55 | 2024 | |
| Travere Therapeutics, INC. | $13.40 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Schreiber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.